

Overview of key presentations featuring Roche medicines:

Medicine	Abstract title	Abstract number/presentation details
<b>Breast cancer</b>		
Giredestrant	Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2- aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial	#LBA16 late-breaking oral Proffered paper session 1: Breast cancer, metastatic Saturday 18 October 2025 10:15-10:25 CEST
	Preoperative window-of-opportunity study with giredestrant or tamoxifen (tam) in premenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) and Ki67≥10% early breast cancer (EBC): the EMPRESS study (IIS: MEDSIR)*	#294MO mini oral Mini oral session: Breast cancer, early stage Sunday 19 October 2025 10:50-10:55 CEST
Giredestrant plus Itovebi™ (inavolisib)	Interim analysis of giredestrant (GIRE) + inavolisib (INAVO) in MORPHEUS breast cancer (BC): A phase Ib/II study of GIRE treatment (rx) combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)	#508P poster Poster session: Breast cancer, metastatic Monday 20 October 2025 12:00-17:30 CEST
Itovebi™	phase I/Ib trial of inavolisib (INAVO) + pertuzumab (P) + trastuzumab (H) for PIK3CA-mutated (mut), HER2-positive advanced breast cancer (HER2+ aBC)	#548P poster Poster session: Breast cancer, metastatic Monday 20 October 2025 12:00-17:30 CEST
<b>Genitourinary cancer</b>		
Tecentriq® (atezolizumab)	IMvigor011: a phase III trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer	#LBA8 late-breaking oral Presidential Symposium III Monday 20 October 2025 16:30-16:42 CEST
<b>Lung cancer</b>		
Alecensa® (alectinib)	Final overall survival (OS) and safety analysis of the phase III ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC)	#LBA73 late-breaking oral Proffered paper session: NSCLC metastatic Friday 17 October 2025 17:06-17:16 CEST
	Updated results from the phase III ALINA study of adjuvant alectinib vs chemotherapy (chemo) in patients (pts) with early-stage ALK+ non-small cell lung cancer (NSCLC)	#1787MO mini oral Mini oral session 2: Non-metastatic NSCLC Monday 20 October 2025 14:50-14:55 CEST
Tecentriq	Patterns of disease progression (PD) and efficacy associated with tumour burden from the phase III IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in ES-SCLC	#2762MO mini oral Mini Oral session 1: Non-metastatic NSCLC Saturday 18 October 2025 17:15-17:20 CEST
<b>Gastrointestinal cancer</b>		
Tecentriq	Clinical outcome of patients (pts) with sporadic vs Lynch syndrome-related stage III colon carcinoma (CC) with deficient mismatch	#752P poster Poster session: Colorectal cancer Sunday 19 October 2025

(IIS: NCI, Alliance)**	repair (dMMR) treated in a randomized trial of adjuvant FOLFOX alone or combined with atezolizumab (atezo; anti-PD-L1)	
Divarasib	Single-agent divarasib experience in patients with KRAS G12C-positive pancreatic adenocarcinoma (panc), cholangiocarcinoma (cholangio), and other solid tumors	#927MO mini oral Mini oral session: Developmental therapeutics Friday 17 October 2025 17:00-17:05 CEST

\* Investigator Initiated Study (IIS). The study is sponsored by MEDSIR and supported by Genentech, a member of the Roche Group.

\*\* Investigator Initiated Study (IIS). The study is sponsored by the National Cancer Institute (NCI), conducted by the Alliance for Clinical Trials in Oncology and supported by Genentech, a member of the Roche Group.